BPC-157 (5 mg Vial) Protocol

BPC-157 is one of the most-discussed peptides in the research community, studied primarily for gut lining repair, tendon and ligament healing, and general tissue recovery. This page walks through a 5 mg vial specifically. It covers how the vial is reconstituted, the syringe math, and the titration pattern most commonly referenced when people discuss handling this compound. For the underlying published research (mechanism, study types, citations), see the BPC-157 research notes.

Quick reference

Reconstitution and syringe math

For a 5 mg vial, adding 2 mL of bacteriostatic water gives a concentration of 2,500 mcg per mL. On a standard U-100 insulin syringe, where 100 units equals 1 mL, that concentration keeps common doses in an easy-to-read range of the barrel.

1. The vial and the bacteriostatic water are usually brought to room temperature first, with both stoppers wiped with an alcohol swab.
2. 2 mL of bacteriostatic water is commonly added slowly, down the inside wall rather than onto the powder, to avoid foaming.
3. The vial is swirled, not shaken, until the powder is fully dissolved and the solution is clear and colorless.
4. Vials are commonly labeled with the concentration and the date of reconstitution.
5. Between draws the vial is kept refrigerated, with a fresh sterile syringe used for each draw.

Worked example: a 250 mcg dose at 2,500 mcg/mL works out to 0.1 mL, which is 10 units on a 100-unit syringe. A 500 mcg dose is double that: 0.2 mL, or 20 units. The full method behind this math (and a calculator you can plug your own numbers into) is on the bac water and syringe math guide.

Titration schedule researchers commonly reference

There's no single official protocol for BPC-157. What follows is the pattern most often referenced in the research community, and it is distinct from TB-500's cadence. BPC-157 is more commonly discussed on a twice-daily schedule rather than a weekly one. It is not drawn from a completed human dose-finding trial; treat it as a measurement reference, not instructions to follow.

A single 5 mg vial, reconstituted this way, supplies exactly 20 doses at the 250 mcg mark, which is about ten days on the twice-daily pattern above. The number worth carrying into a price comparison isn't a vial count though, it's the total milligrams: a twice-daily 4–6 week window works out to roughly 14–21 mg of BPC-157, and a once-daily one to about 7–10 mg.

Supplies for a full cycle

• BPC-157, total quantity: roughly 14–21 mg for a twice-daily 4–6 week window, or about 7–10 mg once daily. Vials are sold in several sizes, commonly 5 mg, 10 mg and 40 mg, so compare on price per milligram rather than counting vials
• Insulin syringes (U-100, 1 mL): roughly one per draw, so 56–84 for a twice-daily 4–6 week window
• Bacteriostatic water: one 10 mL bottle comfortably covers several reconstitutions
• Alcohol swabs: one 100-count box covers a 4–6 week window with room to spare

Storage and handling

The sealed lyophilized vial is kept at room temperature or refrigerated, away from light. Once reconstituted it is refrigerated at 2–8°C and used within about 4–6 weeks, as most commonly referenced by suppliers. Freezing the reconstituted solution is generally avoided, as are repeated freeze-thaw cycles. A new sterile syringe is used for each draw rather than re-entering the vial with a used needle, and site rotation is commonly referenced to limit local irritation.

How BPC-157 works

BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a protective protein found in human gastric juice. It's studied for gut lining repair and mucosal integrity, and for its influence on tendon, ligament, and muscle healing, largely through preclinical animal models alongside a small number of human trials in inflammatory bowel conditions and joint pain.[1][6] The full mechanism and research areas are covered in more depth on the BPC-157 research notes page.

What's reported

From published research:

• Tendon outgrowth and improved cell survival and migration in preclinical tendon-repair models[5]
• Accelerated recovery in animal models of muscle crush and transection injury[2]
• Reported pain relief in a small human retrospective series on intra-articular injection for knee pain[6]
• No LD1 established in animal safety studies, and no reported toxicity in human Phase II trials for ulcerative colitis and multiple sclerosis[4]

Commonly reported in the community (not clinical data):

• Generally described as well tolerated at the doses in the table above
• Occasional mild injection-site redness or tenderness
• No completed large-scale human randomized controlled trial for musculoskeletal use specifically, so this category of report should be weighted accordingly[3]